Antibody-drug conjugates (ADCs): all 1,111 studies that test it
Page 2 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)RecruitingNCT07419295Phase 3
- Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCLNot yet recruitingNCT07415980Phase 1/2
- Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.RecruitingNCT07407465Phase 2
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)RecruitingNCT07405151Phase 1/2
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingNCT07397832Phase 2
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT07393555Phase 2
- Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNot yet recruitingNCT07388875Phase 2
- A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyRecruitingNCT07375316Phase 2
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementRecruitingNCT07371585Phase 2
- Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast CancerRecruitingNCT07371208Phase 2
- Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast CancerNot yet recruitingNCT07368543Phase 2
- RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC FailureNot yet recruitingNCT07366840Phase 2/3
- Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBCEnrolling by invitationNCT07359404Phase 2
- A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical CancerNot yet recruitingNCT07348861Phase 2
- Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination TherapyRecruitingNCT07347314Phase 2
- The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder CancerNot yet recruitingNCT07346053Phase 3
- A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial TumorsNot yet recruitingNCT07343453Phase 2
- Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor TherapyRecruitingNCT07340164Phase 2
- Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingNCT07339059Phase 2
- Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT07329322Phase 2
- Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaRecruitingNCT07324629Phase 2
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerRecruitingNCT07323641Phase 2
- Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung CancerRecruitingNCT07323056Phase 2
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)RecruitingNCT07318558Phase 3
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07315750Phase 3
- Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT07314619Phase 2
- Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical StudyRecruitingNCT07311577Phase 2
- First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.RecruitingNCT07299409Phase 2
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsRecruitingNCT07291037Phase 3
- Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line TreatmentRecruitingNCT07285941Phase 2
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingNCT07285239Phase 3
- A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder CancerNot yet recruitingNCT07279597Phase 2
- Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentRecruitingNCT07275216Phase 2
- TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast CancerNot yet recruitingNCT07271992Phase 2
- BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasEnrolling by invitationNCT07258680Phase 3
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RecruitingNCT07252739Phase 2
- Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07244926Phase 2
- Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBCNot yet recruitingNCT07244874Phase 2
- Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaNot yet recruitingNCT07231250Phase 2
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingNCT07227597Phase 1/2
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingNCT07224672Phase 2
- Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial CarcinomaRecruitingNCT07221942Phase 2
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RecruitingNCT07216703Phase 3
- A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerRecruitingNCT07205822Phase 3
- ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerRecruitingNCT07198724Phase 1/2
- Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT07197307Phase 2
- Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain MetastasisNot yet recruitingNCT07197008Phase 2
- Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.RecruitingNCT07195344Phase 4
- Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric CancerRecruitingNCT07194005Phase 2
- Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNot yet recruitingNCT07193160Phase 2
- Circulating Tumor DNA Response In Urothelial CancerRecruitingNCT07183319Phase 2
- SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd TreatmentRecruitingNCT07182721Phase 2
- Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)RecruitingNCT07179783Phase 2
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingNCT07178730Phase 3
- Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant MaintenanceNot yet recruitingNCT07178457Phase 3
- The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CCNot yet recruitingNCT07172217Phase 2
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingNCT07163481Phase 1
- Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07159217Phase 2
- CVL006 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07157956Phase 1/2
- Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast CancerNot yet recruitingNCT07153965Phase 2
- Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerNot yet recruitingNCT07151586Phase 2
- A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral ResectionNot yet recruitingNCT07142200Phase 2
- Study of EV for Recurrent Endometrial CarcinomaRecruitingNCT07139977Phase 2
- Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast CancerNot yet recruitingNCT07139470Phase 1/2
- Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain MetastasesRecruitingNCT07134153Phase 1/2
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT07129993Phase 2/3
- A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07128693Phase 2
- Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI CancersNot yet recruitingNCT07126561Phase 2
- Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07122609Phase 2
- A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's DiseaseRecruitingNCT07117851Phase 2
- DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingNCT07110038Phase 2
- SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast CancerNot yet recruitingNCT07109284Phase 2
- A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07108816Phase 2
- RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC PatientsNot yet recruitingNCT07100184Phase 2
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07098338Phase 2
- Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II StudyRecruitingNCT07093866Phase 2
- Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCRecruitingNCT07088211Phase 2
- The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard TherapyNot yet recruitingNCT07077564Phase 2
- A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyRecruitingNCT07071337Phase 3
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingNCT07069712Phase 2
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseRecruitingNCT07069595Phase 2
- Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerRecruitingNCT07068542Not applicable
- A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)RecruitingNCT07063212Phase 2
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingNCT07060807Phase 3
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerRecruitingNCT07059845Phase 2
- A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)Not yet recruitingNCT07054242Phase 2
- A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCNot yet recruitingNCT07040644Phase 2
- A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1Not yet recruitingNCT07034508Phase 2
- A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingRecruitingNCT07022483Phase 3
- A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPYNot yet recruitingNCT07019545Phase 2
- A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid TumorsRecruitingNCT07015697Phase 1
- Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLRecruitingNCT07013565Phase 2
- Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingNCT07012980Phase 2
- Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationRecruitingNCT07012031Phase 1/2
- Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)RecruitingNCT07011654Phase 1/2
- Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBCNot yet recruitingNCT07007780Phase 2
- BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingNCT07002216Phase 2
- Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06992739Phase 2